ネツピタント
- ¥12100 - ¥48500
- 化学名: ネツピタント
- 英語名: 2-[3,5-bis(trifluoromethyl)phenyl]-N,2-dimethyl-N-[4-(2-methylphenyl)-6-(4-methylpiperazin-1-yl)pyridin-3-yl]propanamide
- 別名:ネツピタント;2-[3,5-ビス(トリフルオロメチル)フェニル]-N,2-ジメチル-N-[4-(2-メチルフェニル)-6-(4-メチルピペラジン-1-イル)ピリジン-3-イル]プロパンアミド;N-メチル-N-[6-(4-メチルピペラジン-1-イル)-4-(2-メチルフェニル)ピリジン-3-イル]-2-[3,5-ビス(トリフルオロメチル)フェニル]-2-メチルプロパンアミド;N-メチル-N-[4-(2-メチルフェニル)-6-(4-メチルピペラジノ)-3-ピリジニル]-2-メチル-2-[3,5-ビス(トリフルオロメチル)フェニル]プロパンアミド;アキンゼオ
- CAS番号: 290297-26-6
- 分子式: C30H32F6N4O
- 分子量: 578.59
- EINECS:1308068-626-2
- MDL Number:MFCD25976831
2物価
選択条件:
ブランド
- Sigma-Aldrich Japan
パッケージ
- 10MG
- 50MG
- 生産者Sigma-Aldrich Japan
- 製品番号SML2755
- 製品説明 ≥98% (HPLC)
- 英語製品説明Netupitant ≥98% (HPLC)
- 包装単位10MG
- 価格¥12100
- 更新しました2024-03-01
- 購入
- 生産者Sigma-Aldrich Japan
- 製品番号SML2755
- 製品説明 ≥98% (HPLC)
- 英語製品説明Netupitant ≥98% (HPLC)
- 包装単位50MG
- 価格¥48500
- 更新しました2024-03-01
- 購入
生産者 | 製品番号 | 製品説明 | 包装単位 | 価格 | 更新時間 | 購入 |
---|---|---|---|---|---|---|
Sigma-Aldrich Japan | SML2755 | ≥98% (HPLC) Netupitant ≥98% (HPLC) |
10MG | ¥12100 | 2024-03-01 | 購入 |
Sigma-Aldrich Japan | SML2755 | ≥98% (HPLC) Netupitant ≥98% (HPLC) |
50MG | ¥48500 | 2024-03-01 | 購入 |
プロパティ
融点 :156.2-160.0 °C
沸点 :597.4±50.0 °C(Predicted)
比重(密度) :1.255
貯蔵温度 :2-8°C
溶解性 :Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly)
酸解離定数(Pka) :7.89±0.38(Predicted)
外見 :Solid
色 :White to Off-White
InChIKey :WAXQNWCZJDTGBU-UHFFFAOYSA-N
SMILES :C(N(C)C1=C(C2C=CC=CC=2C)C=C(N2CCN(C)CC2)N=C1)(=O)C(C1C=C(C(F)(F)F)C=C(C(F)(F)F)C=1)(C)C
沸点 :597.4±50.0 °C(Predicted)
比重(密度) :1.255
貯蔵温度 :2-8°C
溶解性 :Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly)
酸解離定数(Pka) :7.89±0.38(Predicted)
外見 :Solid
色 :White to Off-White
InChIKey :WAXQNWCZJDTGBU-UHFFFAOYSA-N
SMILES :C(N(C)C1=C(C2C=CC=CC=2C)C=C(N2CCN(C)CC2)N=C1)(=O)C(C1C=C(C(F)(F)F)C=C(C(F)(F)F)C=1)(C)C
安全情報
絵表示(GHS): | ||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
注意喚起語: | Warning | |||||||||||||||||||||
危険有害性情報: |
|
|||||||||||||||||||||
注意書き: |
|
説明
Netupitant, originally developed by Helsinn Healthcare and later licensed to Eisai, Inc., was approved in the USA in October 2014 for the treatment of chemotherapy-induced nausea and emesis. Akynzeo ® is a fixed-dose combination of the new drug netupitant and the previously-approved 5-HT3 antagonist palonosetron. While palonosetron obtained approval previously for treating nausea and emesis occurring within the first 24 hours (acute phase) after chemotherapy, netupitant provides a synergistic effect with palonosetron, assisting in prevention of nausea and emesis in later stages following chemotherapy (25–120 h after chemotherapy treatment). Several clinical trials showed that this combination of netupitant and palonosetron (Akynzeo ?), in comparison to treatment with palonosetron treatment alone, led to an improved percentage of patients in all phases who did not experience any nausea and emesis after undergoing chemotherapy. Netupitant itself joins the class of selective Neurokinin- 1 (NK1) receptor antagonists which, in addition to their use for treating chemotherapy-induced nausea and emesis, also play an important role as therapies for depression and anxiety.供給者とメーカー
Aceschem Inc.
Hebei Chuanghai Biotechnology Co,.LTD
shandong perfect biotechnology co.ltd
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
Beijing Cooperate Pharmaceutical Co.,Ltd
Henan Tianfu Chemical Co.,Ltd.
ATK CHEMICAL COMPANY LIMITED
TianYuan Pharmaceutical CO.,LTD
BOC Sciences
CONIER CHEM AND PHARMA LIMITED